What is Amphastar Pharmaceuticals, Inc.'s earnings per share (EPS)?

Amphastar Pharmaceuticals, Inc. (AMPH) reported diluted earnings per share of $2.03 for fiscal year 2025. This represents a -33.7% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Amphastar Pharmaceuticals (AMPH) Financials

AMPH NASDAQ

Trailing 12 months to June 30, 2026

Revenue $730.0M +1.0% YoY

Net Income $78.5M -41.7% YoY

EPS (Diluted) $1.69 -36.7% YoY

Free Cash Flow $152.9M +36.3% YoY

Market Cap $1.1B as of Oct 28, 2026

Price / Sales 1.5x on $730.0M revenue, trailing 12 months to June 30, 2026

Price / Earnings 14.3x on $78.5M net income, trailing 12 months to June 30, 2026

Price / Book 1.5x on $768.2M equity, Q2 FY2026

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 28, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period Q2 FY2026, ended Jun 30, 2026 Reported Aug 6, 2026 Currency USD FYE December

Newest figures come from the 10-Q for Q2 FY2026, filed Aug 6, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the AMPH SEC filings page.

Amphastar Pharmaceuticals, Inc. (AMPH) reported $730.0M in revenue over the twelve months to Jun 30, 2026, up 1.0% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 14 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI AMPH FY2025 2026-10-24

Revenue held roughly flat in FY2025, but higher operating spending sharply reduced profit while cash generation remained positive.

The key shift was operating-cost pressure rather than demand collapse: revenue fell -1.7% while SG&A rose 37.3%. That combination pulled operating margin from 28.1% to 19.5%, showing the earnings drop came mainly from higher expenses and weaker gross margin, not a comparable loss of sales.

Cash conversion remained favorable: operating cash flow was $156.1M against net income of $98.1M. The conversion ratio was 159.1%, up from 133.8% in FY2024, meaning cash generation outpaced accounting profit even as both declined.

Working capital became more demanding: inventory rose 15.1% while revenue fell 1.7%, suggesting more capital was committed to stock despite softer sales. At the same time, the current ratio was 4.0x and liabilities were 51.6% of assets, leaving short-term coverage stronger than the recent earnings trend.

Financial Health Signals

Financial Health Score 69/100

Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group, and the overall is the average of the dimensions that can be computed. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →

Health score ≠ stock price. This rates the quality of Amphastar Pharmaceuticals, Inc.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Profitability

Amphastar Pharmaceuticals, Inc. has an operating margin of 19.5%, meaning the company retains $20 of operating profit per $100 of revenue. This strong profitability earns a score of 83/100, reflecting efficient cost management and pricing power. This is down from 28.1% the prior year.

Growth

Amphastar Pharmaceuticals, Inc.'s revenue declined 1.7% year-over-year, from $732.0M to $719.9M. This contraction results in a growth score of 52/100.

Leverage

Amphastar Pharmaceuticals, Inc. has elevated debt relative to equity (D/E of 0.79), meaning the company relies heavily on borrowed funds. This high leverage results in a low score of 28/100, reflecting increased financial risk.

Liquidity

With a current ratio of 4.02, Amphastar Pharmaceuticals, Inc. holds $4.02 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 87/100.

Cash Flow

Amphastar Pharmaceuticals, Inc. converts 16.8% of revenue into free cash flow ($121.2M). This strong cash generation earns a score of 86/100.

Returns

Amphastar Pharmaceuticals, Inc. earns a strong 12.4% return on equity (ROE), meaning it generates $12 of profit for every $100 of shareholders' equity. This efficient capital use earns a returns score of 76/100. This is down from 21.8% the prior year.

Altman Z-Score Grey Zone

2.45

Amphastar Pharmaceuticals, Inc. scores 2.45, placing it in the grey zone between 1.81 and 2.99. The largest contribution to the score comes from a market capitalization of $1.1B against total liabilities of $840.5M. This signals moderate financial risk that warrants monitoring.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Neutral

6/9

Amphastar Pharmaceuticals, Inc. passes 6 of 9 financial strength tests. 3 of 4 profitability signals pass, all 3 leverage/liquidity signals pass, neither operating efficiency signal passes.

Earnings Quality Cash-Backed

1.59x

For every $1 of reported earnings, Amphastar Pharmaceuticals, Inc. generates $1.59 in operating cash flow ($156.1M OCF vs $98.1M net income). This indicates profits are well-supported by actual cash generation, not accounting adjustments.

Interest Coverage Safe

5.51x

Amphastar Pharmaceuticals, Inc. earns $5.51 in operating income for every $1 of interest expense ($140.4M vs $25.5M). This wide margin provides strong safety for debt servicing, even if earnings decline temporarily.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$183.9M

YoY+5.4%

QoQ+7.4%

5Y CAGR+12.6%

10Y CAGR+10.5%

Amphastar Pharmaceuticals, Inc. generated $183.9M in revenue in Q2 2026. This represents an increase of 5.4% from the same quarter a year earlier. Against the prior quarter it is up 7.4%.

EBITDA

$54.0M

YoY-4.9%

QoQ+92.9%

5Y CAGR+32.6%

Amphastar Pharmaceuticals, Inc.'s EBITDA was $54.0M in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 4.9% from the same quarter a year earlier. Against the prior quarter it is up 92.9%.

Net Income

$30.3M

YoY-2.2%

QoQ+372.7%

5Y CAGR+31.3%

10Y CAGR+16.0%

Amphastar Pharmaceuticals, Inc. reported $30.3M in net income in Q2 2026. This represents a decrease of 2.2% from the same quarter a year earlier. Against the prior quarter it is up 372.7%.

EPS (Diluted)

$0.67

YoY+4.7%

QoQ+378.6%

5Y CAGR+33.2%

Amphastar Pharmaceuticals, Inc. earned $0.67 per diluted share (EPS) in Q2 2026. This represents an increase of 4.7% from the same quarter a year earlier. Against the prior quarter it is up 378.6%.

Cash & Balance Sheet

Free Cash Flow

$42.7M

YoY+70.7%

QoQ+11.5%

5Y CAGR+10.1%

10Y CAGR+27.0%

Amphastar Pharmaceuticals, Inc. generated $42.7M in free cash flow in Q2 2026, representing cash available after capex. This represents an increase of 70.7% from the same quarter a year earlier. Against the prior quarter it is up 11.5%.

Cash & Debt

$223.6M

YoY+19.1%

QoQ+30.8%

5Y CAGR+16.2%

10Y CAGR+12.9%

Amphastar Pharmaceuticals, Inc. held $223.6M in cash against $609.6M in long-term debt as of Q2 2026.

Shares Outstanding

43M

YoY-8.5%

QoQ-3.5%

5Y CAGR-2.4%

Amphastar Pharmaceuticals, Inc. had 43M shares outstanding in Q2 2026. This represents a decrease of 8.5% from the same quarter a year earlier. Against the prior quarter it is down 3.5%.

Dividends Per Share

Not reported for Q2 2026.

Margins & Returns

Gross Margin

50.8%

YoY+1.2pp

QoQ+9.7pp

5Y change+4.2pp

10Y change+4.2pp

Amphastar Pharmaceuticals, Inc.'s gross margin was 50.8% in Q2 2026, indicating the percentage of revenue retained after direct costs. This is up 1.2 percentage points from the same quarter a year earlier. Against the prior quarter it is up 9.7 percentage points.

Operating Margin

21.6%

YoY-2.6pp

QoQ+13.6pp

5Y change+11.2pp

Amphastar Pharmaceuticals, Inc.'s operating margin was 21.6% in Q2 2026, reflecting core business profitability. This is down 2.6 percentage points from the same quarter a year earlier. Against the prior quarter it is up 13.6 percentage points.

Net Margin

16.5%

YoY-1.3pp

QoQ+12.8pp

5Y change+8.9pp

10Y change+6.4pp

Amphastar Pharmaceuticals, Inc.'s net profit margin was 16.5% in Q2 2026, showing the share of revenue converted to profit. This is down 1.3 percentage points from the same quarter a year earlier. Against the prior quarter it is up 12.8 percentage points.

Return on Equity

4.0%

YoY-0.2pp

QoQ+3.1pp

5Y change+2.1pp

10Y change+1.7pp

Amphastar Pharmaceuticals, Inc.'s quarterly ROE was 4.0% in Q2 2026: one quarter's net income over shareholder equity, not annualized. This is down 0.2 percentage points from the same quarter a year earlier. Against the prior quarter it is up 3.1 percentage points.

Capital Allocation

R&D Spending

$22.2M

YoY+10.4%

QoQ-17.1%

5Y CAGR+4.1%

Amphastar Pharmaceuticals, Inc. invested $22.2M in research and development in Q2 2026. This represents an increase of 10.4% from the same quarter a year earlier. Against the prior quarter it is down 17.1%.

Share Buybacks

$45.2M

YoY+15.3%

QoQ+53.3%

Amphastar Pharmaceuticals, Inc. spent $45.2M on share buybacks in Q2 2026, returning capital to shareholders by reducing shares outstanding. This represents an increase of 15.3% from the same quarter a year earlier. Against the prior quarter it is up 53.3%.

Capital Expenditures

$8.6M

YoY-18.7%

QoQ-9.6%

5Y CAGR+8.4%

10Y CAGR+4.8%

Amphastar Pharmaceuticals, Inc. invested $8.6M in capex in Q2 2026, funding long-term assets and infrastructure. This represents a decrease of 18.7% from the same quarter a year earlier. Against the prior quarter it is down 9.6%.

AMPH Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

AMPH quarterly income statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K
Revenue	$730.0M	$719.9M-1.7%	$732.0M+13.6%	$644.4M+29.1%	$499.0M+14.0%	$437.8M+25.1%	$349.8M+8.5%	$322.4M+9.4%	$294.7M+22.7%	$240.2M-5.9%	$255.2M+1.4%	$251.5M+19.5%	$210.5M-8.4%	$229.7M+12.4%	$204.3M
Cost of Revenue	$381.9M	$363.8M+1.6%	$358.1M+22.1%	$293.3M+17.3%	$250.1M+5.1%	$238.0M+15.3%	$206.5M+8.4%	$190.4M+1.5%	$187.7M+25.4%	$149.7M-0.9%	$151.0M-13.3%	$174.2M+9.4%	$159.2M+11.5%	$142.7M+25.2%	$114.0M
Gross Profit	$348.1M	$356.1M-4.8%	$373.9M+6.5%	$351.1M+41.1%	$248.9M+24.6%	$199.7M+39.3%	$143.3M+8.7%	$131.9M+23.3%	$107.0M+18.2%	$90.5M-13.1%	$104.2M+34.7%	$77.3M+50.9%	$51.3M-41.1%	$87.0M-3.7%	$90.3M
R&D Expenses	$94.6M	$85.8M+16.1%	$73.9M+0.2%	$73.7M-1.4%	$74.8M+22.7%	$60.9M-9.4%	$67.2M-2.4%	$68.9M+19.6%	$57.6M+32.3%	$43.5M+4.8%	$41.5M+11.4%	$37.3M+29.1%	$28.9M-12.6%	$33.0M+6.0%	$31.2M
SG&A Expenses	$139.3M	$129.8M+37.3%	$94.5M+17.6%	$80.4M+20.7%	$66.6M-3.4%	$68.9M+5.8%	$65.2M+3.2%	$63.1M+8.7%	$58.0M+14.0%	$50.9M+7.7%	$47.3M+0.7%	$47.0M+16.4%	$40.4M+11.2%	$36.3M+14.8%	$31.6M
Operating Income	$114.3M	$140.4M-31.7%	$205.4M+4.3%	$197.0M+83.2%	$107.5M+53.8%	$69.9M+538.0%	$11.0Mn/m	-$39Kn/m	-$8.6Mn/m	-$1.3M-108.3%	$15.4Mn/m	-$6.9Mn/m	-$18.0M-202.8%	$17.5M-31.1%	$25.4M
EBITDA	N/A	$197.3M-23.7%	$258.6M+16.1%	$222.7M+85.5%	$120.1M+49.9%	$80.1M+300.9%	$20.0M+184.7%	$7.0Mn/m	-$2.6M-149.9%	$5.2M-82.9%	$30.1M+373.0%	$6.4Mn/m	-$3.5M-111.6%	$30.6M-17.1%	$36.9M
Interest Expense	$26.1M	$25.5M-16.0%	$30.3M+11.7%	$27.2M+1371.2%	$1.8M+108.6%	$885K+136.6%	$374K+214.3%	$119K-51.0%	$243K-70.6%	$826K-19.3%	$1.0M+3.7%	$987K+62.1%	$609K-36.4%	$958K+22.2%	$784K
Income Tax	$23.5M	$25.5M-14.0%	$29.7M-6.8%	$31.8M+35.6%	$23.5M+13.8%	$20.6M+482.8%	$3.5M-74.2%	$13.7Mn/m	-$3.3Mn/m	-$2.4M-149.9%	$4.8Mn/m	-$7.6Mn/m	-$7.4M-238.8%	$5.4M-31.1%	$7.8M
Net Income	$78.5M	$98.1M-38.5%	$159.5M+16.0%	$137.5M+50.5%	$91.4M+47.1%	$62.1M+4327.4%	$1.4M-97.1%	$48.9Mn/m	-$5.7M-257.3%	$3.6M-62.9%	$9.8Mn/m	-$2.8Mn/m	-$10.7M-190.2%	$11.9M-34.4%	$18.1M
EPS (Basic)	N/A	$2.10-36.2%	$3.29+15.4%	$2.85+51.6%	$1.88+44.6%	$1.30+4233.3%	$0.03-97.1%	$1.04n/m	-$0.12-250.0%	$0.08-63.6%	$0.22n/m	-$0.06n/m	-$0.25-180.6%	$0.31-34.0%	$0.47
EPS (Diluted)	$1.69	$2.03-33.7%	$3.06+17.7%	$2.60+49.4%	$1.74+39.2%	$1.25+4066.7%	$0.03-96.9%	$0.98n/m	-$0.12-250.0%	$0.08-61.9%	$0.21n/m	-$0.06n/m	-$0.25-180.6%	$0.31-32.6%	$0.46
Diluted Shares (Avg)	N/A	48M-7.4%	52M-1.8%	53M+1.1%	52M+5.3%	50M+1.3%	49M-1.6%	50M+7.6%	46M-4.1%	48M+1.8%	48M+5.7%	45M+7.2%	42M+7.9%	39M-0.1%	39M

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-K	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Revenue	$183.9M+5.4%	$171.2M+0.4%	$183.1M-1.8%	$191.8M+0.3%	$174.4M-4.4%	$170.5M-0.8%	$186.5M+4.7%	$191.2M+5.9%
Cost of Revenue	$90.4M+2.9%	$100.8M+18.3%	$97.4M-2.4%	$93.2M+4.4%	$87.9M+0.8%	$85.3M+4.3%	$99.9M+21.9%	$89.3M+23.7%
Gross Profit	$93.5M+8.1%	$70.3M-17.5%	$85.7M-1.1%	$98.6M-3.2%	$86.5M-9.1%	$85.3M-5.4%	$86.6M-9.9%	$101.9M-6.0%
R&D Expenses	$22.2M+10.4%	$26.7M+33.0%	$23.3M+28.5%	$22.4M+6.1%	$20.1M+13.8%	$20.1M+17.9%	$18.1M-11.2%	$21.1M+26.5%
SG&A Expenses	$31.6M+30.3%	$30.0M+7.5%	$26.8M+14.5%	$51.0M+114.0%	$24.2M+8.7%	$27.9M+11.2%	$23.4M+7.5%	$23.8M+24.9%
Operating Income	$39.7M-5.8%	$13.6M-63.5%	$35.6M-21.1%	$25.3M-55.6%	$42.2M-23.6%	$37.3M-22.3%	$45.1M-16.4%	$57.0M-21.5%
EBITDA	$54.0M-4.9%	$28.0M-45.0%	$50.1M-19.4%	$39.4M-44.0%	$56.8M-16.9%	$50.9M-11.7%	$62.1M-2.4%	$70.4M-14.4%
Interest Expense	$6.7M+6.0%	$6.6M+4.2%	$6.6M+3.2%	$6.3M-6.2%	$6.3M-27.0%	$6.3M-27.0%	$6.4M-32.1%	$6.7M-51.1%
Income Tax	$8.2M-1.3%	$3.6M-34.9%	$7.5M+24.8%	$4.2M-42.6%	$8.3M-32.4%	$5.6M+35.2%	$6.0M+28.4%	$7.3M-48.3%
Net Income	$30.3M-2.2%	$6.4M-74.6%	$24.4M-35.7%	$17.4M-57.1%	$31.0M-18.2%	$25.3M-41.4%	$38.0M+5.0%	$40.4M-17.9%
EPS (Basic)	$0.69+4.5%	$0.14-73.6%	$0.53-32.9%	$0.38-54.2%	$0.66-14.3%	$0.53-41.1%	$0.79+5.3%	$0.83-17.8%
EPS (Diluted)	$0.67+4.7%	$0.14-72.5%	$0.51-31.1%	$0.37-52.6%	$0.64-12.3%	$0.51-37.0%	$0.74+7.2%	$0.78-14.3%
Diluted Shares (Avg)	44M-8.1%	46M-6.9%	N/A	48M-8.1%	48M-7.5%	50M-5.9%	N/A	52M-3.8%

AMPH Balance Sheet

AMPH quarterly balance sheet

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K
Total Assets	$1.6B+3.3%	$1.6B+4.3%	$1.5B+103.9%	$742.0M+10.5%	$671.5M+6.4%	$631.2M+7.5%	$587.0M+14.3%	$513.6M+13.9%	$451.1M+5.5%	$427.7M+9.6%	$390.1M+0.2%	$389.4M+14.9%	$338.7M	N/A
Current Assets	$636.0M+19.1%	$534.1M+9.1%	$489.6M+29.4%	$378.3M+18.9%	$318.1M+13.7%	$279.7M+9.6%	$255.2M+15.8%	$220.3M+17.3%	$187.8M+2.0%	$184.1M+4.6%	$175.9M-11.1%	$198.0M+14.5%	$173.0M	N/A
Cash & Equivalents	$170.2M+12.2%	$151.6M+5.1%	$144.3M-7.6%	$156.1M+23.5%	$126.4M+36.4%	$92.6M+25.7%	$73.7M-14.7%	$86.3M+31.6%	$65.6M-9.3%	$72.4M+9.5%	$66.1M-2.6%	$67.8M+26.6%	$53.6M+6.7%	$50.2M
Short-Term Investments	$112.6M+60.8%	$70.0M-37.8%	$112.5M+472.2%	$19.7M+90.5%	$10.3M-20.5%	$13.0M+11.2%	$11.7M+312.4%	$2.8M+7.4%	$2.6M+400.0%	$527Kn/m	$0n/m	$0n/m	$0n/m	$0
Inventory	$176.9M+15.1%	$153.7M+45.3%	$105.8M+2.2%	$103.6M+11.6%	$92.8M-4.2%	$96.8M-12.4%	$110.5M+59.4%	$69.3M+9.0%	$63.6M-20.2%	$79.8M+12.9%	$70.7M-14.2%	$82.3M+17.8%	$69.9M	N/A
Accounts Receivable	$143.6M+5.3%	$136.3M+18.6%	$114.9M+29.4%	$88.8M+12.7%	$78.8M+19.4%	$66.0M+45.5%	$45.4M-13.0%	$52.2M+44.9%	$36.0M+34.4%	$26.8M-19.4%	$33.2M+45.4%	$22.9M-7.0%	$24.6M	N/A
Long-Term Investments	$0-100.0%	$11.0M-25.1%	$14.7Mn/m	$0n/m	$0n/m	$0n/m	$0n/m	$0n/m	$0n/m	$0n/m	$0n/m	$0n/m	$0n/m	$0
Goodwill	$3.4M+11.6%	$3.0M-5.2%	$3.2M+2.9%	$3.1M-5.6%	$3.3M-15.9%	$3.9M+8.4%	$3.6M-8.0%	$4.0M-11.4%	$4.5M+12.2%	$4.0M+6.7%	$3.7M-16.6%	$4.5M+1495.4%	$280K0.0%	$280K
Total Liabilities	$840.5M-0.6%	$845.2M-3.2%	$873.5M+309.5%	$213.3M-5.6%	$226.0M+23.8%	$182.5M+14.5%	$159.4M+6.9%	$149.2M+27.2%	$117.3M+19.1%	$98.5M+4.1%	$94.6M-12.0%	$107.5M+23.3%	$87.2M	N/A
Current Liabilities	$158.2M-9.0%	$173.8M-22.9%	$225.4M+137.6%	$94.9M-8.6%	$103.8M-7.5%	$112.2M+24.7%	$90.0M-15.7%	$106.8M+59.0%	$67.2M+10.8%	$60.6M+1.1%	$60.0M-4.2%	$62.6M-4.3%	$65.4M	N/A
Non-Current Liabilities	$682.3M+1.6%	$671.4M+3.6%	$648.1M+447.1%	$118.5M-3.1%	$122.2M+73.8%	$70.3M+1.3%	$69.4M+63.9%	$42.4M-15.5%	$50.1M+32.4%	$37.9M+9.2%	$34.7M-22.8%	$44.9M+106.0%	$21.8M	N/A
Long-Term Debt	$619.7M+1.0%	$613.5M+1.7%	$603.2M+687.0%	$76.6M-2.0%	$78.2M+70.3%	$45.9M-0.9%	$46.3M-5.6%	$49.1M+7.4%	$45.7M+26.9%	$36.0M-10.6%	$40.3M-5.6%	$42.7M+323.9%	$10.1M	N/A
Total Equity	$788.8M+7.7%	$732.3M+14.5%	$639.4M+21.0%	$528.7M+18.7%	$445.5M+10.7%	$402.3M+5.5%	$381.4M+14.7%	$332.4M-0.4%	$333.7M+1.4%	$329.3M+11.4%	$295.5M+4.8%	$281.9M+12.1%	$251.5M+7.8%	$233.4M
Retained Earnings	$666.9M+17.2%	$568.8M+39.0%	$409.3M+50.6%	$271.7M+50.7%	$180.3M+53.1%	$117.8M+1.2%	$116.4M+72.4%	$67.5M-7.1%	$72.6M+2.5%	$70.9M+17.5%	$60.3M-4.4%	$63.1M-14.5%	$73.8M	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-K	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Total Assets	$1.7B+8.0%	$1.6B+1.3%	$1.6B+3.3%	$1.7B+7.8%	$1.6B+8.3%	$1.6B+3.3%	$1.6B+4.3%	$1.5B0.0%
Current Assets	$631.0M+8.6%	$633.7M+7.8%	$636.0M+19.1%	$639.5M+17.1%	$580.8M+20.3%	$588.0M+5.9%	$534.1M+9.1%	$545.9M+0.5%
Cash & Equivalents	$223.6M+19.1%	$170.9M-6.5%	$170.2M+12.2%	$216.3M+12.6%	$187.7M-1.0%	$182.8M-9.1%	$151.6M+5.1%	$192.1M-28.0%
Short-Term Investments	$66.5M+50.9%	$121.0M+123.7%	$112.6M+60.8%	$59.9M+2.7%	$44.1M+56.5%	$54.1M-38.8%	$70.0M-37.8%	$58.4M+76.4%
Inventory	$179.9M-6.2%	$170.2M-8.2%	$176.9M+15.1%	$185.9M+42.7%	$191.7M+56.6%	$185.5M+60.6%	$153.7M+45.3%	$130.3M+18.5%
Accounts Receivable	$144.9M+8.9%	$147.8M+2.2%	$143.6M+5.3%	$146.8M+5.1%	$133.0M+1.2%	$144.6M+4.7%	$136.3M+18.6%	$139.6M+17.4%
Long-Term Investments	$0-100.0%	$0-100.0%	$0-100.0%	$0n/m	$2.0M-79.4%	$5.9M-61.0%	$11.0M-25.1%	$0-100.0%
Goodwill	$3.3M-2.5%	$3.3M+5.5%	$3.4M+11.6%	$3.4M+4.5%	$3.4M+8.6%	$3.2M+0.2%	$3.0M-5.2%	$3.3M+5.3%
Total Liabilities	$975.6M+13.7%	$874.8M0.0%	$840.5M-0.6%	$889.5M+8.8%	$857.9M+10.2%	$875.0M-3.0%	$845.2M-3.2%	$817.5M-13.9%
Current Liabilities	$263.2M+49.2%	$164.5M-17.4%	$158.2M-9.0%	$205.2M+29.1%	$176.4M+28.8%	$199.1M-22.0%	$173.8M-22.9%	$159.0M-38.4%
Non-Current Liabilities	$712.4M+4.5%	$710.3M+5.1%	$682.3M+1.6%	$684.2M+3.9%	$681.4M+6.3%	$675.9M+4.5%	$671.4M+3.6%	$658.5M-4.8%
Long-Term Debt	$609.6M+0.3%	$609.8M+1.0%	$619.7M+1.0%	$608.6M+2.0%	$607.7M+3.6%	$603.9M+1.7%	$613.5M+1.7%	$596.4M-8.7%
Total Equity	$768.2M+1.4%	$773.4M+2.9%	$788.8M+7.7%	$776.7M+6.7%	$757.5M+6.2%	$751.3M+11.7%	$732.3M+14.5%	$727.7M+22.3%
Retained Earnings	$703.6M+12.6%	$673.3M+13.3%	$666.9M+17.2%	$642.5M+21.0%	$625.1M+27.5%	$594.1M+31.3%	$568.8M+39.0%	$530.8M+42.3%

AMPH Cash Flow Statement

AMPH quarterly cash flow statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K
Operating Cash Flow	$184.6M	$156.1M-26.8%	$213.4M+16.3%	$183.5M+105.8%	$89.2M-9.0%	$98.0M+71.1%	$57.3M+37.1%	$41.8M+9.4%	$38.2M-2.6%	$39.2M+1.7%	$38.6M+261.0%	$10.7M-49.3%	$21.1M-32.2%	$31.0Mn/m	-$1.6M
Depreciation & Amortization	N/A	$56.9M+7.0%	$53.1M+106.5%	$25.7M+104.3%	$12.6M+23.2%	$10.2M+13.2%	$9.0M+27.9%	$7.1M+16.6%	$6.1M-5.7%	$6.4M-56.3%	$14.7M+10.8%	$13.3M-8.3%	$14.4M+10.5%	$13.1M+13.8%	$11.5M
Stock-Based Compensation	N/A	$27.3M+11.9%	$24.4M+20.4%	$20.2M+13.3%	$17.9M-4.4%	$18.7M-8.8%	$20.5M+18.5%	$17.3M+3.7%	$16.7M-2.4%	$17.1M+13.0%	$15.1M+18.0%	$12.8M+38.1%	$9.3M+52.4%	$6.1M-8.8%	$6.7M
Capital Expenditures	$31.7M	$34.9M-15.0%	$41.0M+7.5%	$38.2M+58.8%	$24.0M-12.5%	$27.5M-18.9%	$33.9M-18.5%	$41.6M-11.2%	$46.8M+33.4%	$35.1M+64.2%	$21.4M+33.7%	$16.0M-22.0%	$20.5M+16.2%	$17.6M-23.7%	$23.1M
Free Cash Flow	$152.9M	$121.2M-29.7%	$172.3M+18.6%	$145.3M+123.1%	$65.1M-7.6%	$70.5M+201.3%	$23.4M+11209.7%	$207Kn/m	-$8.6M-309.7%	$4.1M-76.1%	$17.2Mn/m	-$5.3M-1061.1%	$553K-95.9%	$13.4Mn/m	-$24.8M
Investing Cash Flow	-$52.1M	-$70.3Mn/m	-$124.9Mn/m	-$649.1Mn/m	-$32.8Mn/m	-$28.7Mn/m	-$36.4Mn/m	-$50.5Mn/m	-$42.2Mn/m	-$36.9Mn/m	-$39.5Mn/m	-$16.9M	N/A	N/A	N/A
Financing Cash Flow	-$96.5M	-$67.4Mn/m	-$81.0M-117.8%	$454.1Mn/m	-$26.4Mn/m	-$37.0Mn/m	-$2.2Mn/m	-$3.8M-115.1%	$25.0Mn/m	-$7.7M-208.1%	$7.1M+219.2%	$2.2M	N/A	N/A	N/A
Share Buybacks	$100.1M	$75.6M-11.6%	$85.5M+47.0%	$58.1M+45.7%	$39.9M+38.2%	$28.9M+18.2%	$24.4M+9.6%	$22.3M-11.0%	$25.0M-18.5%	$30.7M+210.3%	$9.9M+0.4%	$9.9M+2759.4%	$345K+73.4%	$199K-75.5%	$811K

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-K	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Operating Cash Flow	$51.3M+44.2%	$47.8M+36.4%	$32.9M+13.2%	$52.6M-12.3%	$35.6M-48.5%	$35.1M-36.6%	$29.0M+21.6%	$60.0M-6.8%
Depreciation & Amortization	$14.3M-2.1%	$14.4M+5.4%	$14.5M-14.7%	$14.1M+5.4%	$14.6M+11.2%	$13.7M+41.3%	$16.9M+75.4%	$13.4M+39.3%
Stock-Based Compensation	$7.1M+11.1%	$9.3M+10.5%	N/A	$6.3M+12.5%	$6.4M+10.4%	$8.4M+14.0%	N/A	$5.6M+20.5%
Capital Expenditures	$8.6M-18.7%	$9.5M-11.1%	$8.3M-33.3%	$5.3M-61.2%	$10.6M+74.8%	$10.7M+21.7%	$12.4M+31.4%	$13.8M+35.3%
Free Cash Flow	$42.7M+70.7%	$38.3M+57.2%	$24.6M+48.0%	$47.2M+2.3%	$25.0M-60.3%	$24.4M-47.6%	$16.6M+15.2%	$46.2M-14.7%
Investing Cash Flow	$44.9Mn/m	-$16.7M-259.7%	-$60.6Mn/m	-$19.6Mn/m	-$625Kn/m	$10.5M-31.2%	-$35.7Mn/m	-$34.6Mn/m
Financing Cash Flow	-$43.5Mn/m	-$30.2Mn/m	-$18.4Mn/m	-$4.3Mn/m	-$30.2Mn/m	-$14.5Mn/m	-$33.8Mn/m	-$22.8M-126.3%
Share Buybacks	$45.2M+15.3%	$29.5M+168.1%	$20.5M-51.2%	$4.8M-86.1%	$39.2M	$11.0M	$42.0Mn/m	$35.0M-30.1%

Not reported in any period shown, so not listed: Dividends Paid.

AMPH Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

AMPH quarterly financial ratios

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K
Gross Margin	49.5%-1.6pp	51.1%-3.4pp	54.5%+4.6pp	49.9%+4.2pp	45.6%+4.7pp	41.0%+0.1pp	40.9%+4.6pp	36.3%-1.4pp	37.7%-3.1pp	40.8%+10.1pp	30.8%+6.4pp	24.3%-13.5pp	37.9%-6.3pp	44.2%
Operating Margin	19.5%-8.6pp	28.1%-2.5pp	30.6%+9.0pp	21.5%+5.6pp	16.0%+12.8pp	3.1%+3.1pp	0.0%+2.9pp	-2.9%-2.4pp	-0.5%-6.6pp	6.0%+8.8pp	-2.7%+5.8pp	-8.5%-16.2pp	7.6%-4.8pp	12.4%
Net Margin	13.6%-8.2pp	21.8%+0.5pp	21.3%+3.0pp	18.3%+4.1pp	14.2%+13.8pp	0.4%-14.8pp	15.2%+17.1pp	-1.9%-3.5pp	1.5%-2.3pp	3.9%+5.0pp	-1.1%+4.0pp	-5.1%-10.2pp	5.2%-3.7pp	8.9%
Return on Equity	12.4%-9.3pp	21.8%+0.3pp	21.5%+4.2pp	17.3%+3.4pp	13.9%+13.6pp	0.4%-12.5pp	12.8%+14.6pp	-1.7%-2.8pp	1.1%-1.9pp	3.0%+3.9pp	-0.9%+2.9pp	-3.8%-8.5pp	4.7%-3.0pp	7.8%
Return on Assets	6.0%-4.1pp	10.1%+1.0pp	9.1%-3.2pp	12.3%+3.1pp	9.3%+9.0pp	0.2%-8.1pp	8.3%+9.5pp	-1.1%-1.9pp	0.8%-1.5pp	2.3%+3.0pp	-0.7%+2.0pp	-2.8%-6.3pp	3.5%	N/A
Current Ratio	4.02+0.9x	3.07+0.9x	2.17-1.8x	3.99+0.9x	3.06+0.6x	2.49-0.3x	2.84+0.8x	2.06-0.7x	2.79-0.2x	3.04+0.1x	2.93-0.2x	3.16+0.5x	2.64	N/A
Debt-to-Equity	0.79-0.1x	0.84-0.1x	0.94+0.8x	0.140.0x	0.18+0.1x	0.110.0x	0.120.0x	0.150.0x	0.140.0x	0.110.0x	0.140.0x	0.15+0.1x	0.04	N/A
Liabilities-to-Equity	1.07-0.1x	1.15-0.2x	1.37+1.0x	0.40-0.1x	0.51+0.1x	0.450.0x	0.420.0x	0.45+0.1x	0.35+0.1x	0.300.0x	0.32-0.1x	0.380.0x	0.35	N/A
Asset Turnover	0.440.0x	0.460.0x	0.43-0.2x	0.670.0x	0.65+0.1x	0.550.0x	0.550.0x	0.570.0x	0.53-0.1x	0.600.0x	0.64+0.1x	0.54-0.1x	0.68	N/A
FCF Margin	16.8%-6.7pp	23.5%+1.0pp	22.6%+9.5pp	13.1%-3.0pp	16.1%+9.4pp	6.7%+6.6pp	0.1%+3.0pp	-2.9%-4.6pp	1.7%-5.0pp	6.7%+8.8pp	-2.1%-2.4pp	0.3%-5.6pp	5.8%+18.0pp	-12.1%

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-K	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Gross Margin	50.8%+1.2pp	41.1%-8.9pp	46.8%+0.3pp	51.4%-1.9pp	49.6%-2.6pp	50.0%-2.4pp	46.5%-7.5pp	53.3%-6.7pp
Operating Margin	21.6%-2.6pp	8.0%-13.9pp	19.4%-4.7pp	13.2%-16.6pp	24.2%-6.1pp	21.9%-6.1pp	24.2%-6.1pp	29.8%-10.4pp
Net Margin	16.5%-1.3pp	3.8%-11.1pp	13.3%-7.0pp	9.0%-12.1pp	17.8%-3.0pp	14.8%-10.3pp	20.3%0.0pp	21.1%-6.1pp
Return on Equity	4.0%-0.2pp	0.8%-2.5pp	3.1%-2.1pp	2.2%-3.3pp	4.1%-1.2pp	3.4%-3.0pp	5.2%-0.5pp	5.6%-2.7pp
Return on Assets	1.7%-0.2pp	0.4%-1.2pp	1.5%-0.9pp	1.0%-1.6pp	1.9%-0.6pp	1.6%-1.2pp	2.4%0.0pp	2.6%-0.6pp
Current Ratio	2.40-0.9x	3.85+0.9x	4.02+0.9x	3.12-0.3x	3.29-0.2x	2.95+0.8x	3.07+0.9x	3.43+1.3x
Debt-to-Equity	0.790.0x	0.790.0x	0.79-0.1x	0.780.0x	0.800.0x	0.80-0.1x	0.84-0.1x	0.82-0.3x
Liabilities-to-Equity	1.27+0.1x	1.130.0x	1.07-0.1x	1.150.0x	1.130.0x	1.16-0.2x	1.15-0.2x	1.12-0.5x
Asset Turnover	0.110.0x	0.100.0x	0.110.0x	0.120.0x	0.110.0x	0.100.0x	0.120.0x	0.120.0x
FCF Margin	23.2%+8.9pp	22.4%+8.1pp	13.4%+4.5pp	24.6%+0.5pp	14.3%-20.2pp	14.3%-12.8pp	8.9%+0.8pp	24.1%-5.8pp

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.

Company	Fiscal year	Revenue	Net income	Net margin	Market cap	Health score
Amphastar Pharmaceuticals, Inc. AMPH	FY2025	$719.9M	$98.1M	13.6%	$1.1B	69/100
Harrow, Inc. HROW	FY2025	$272.3M	-$5.1M	-1.9%	$1.1B	51/100
Evotec SE EVO	FY2024	$824.9M	-$203.0M	-24.6%	$570.4M	35/100
Tilray Brands, Inc. TLRY	FY2026	$915.5M	-$121.4M	-13.3%	$397.5M	41/100
BGM Group Ltd. BGM	FY2025	$37.9M	-$19.9M	-52.6%	$129.9M	35/100

Where Amphastar Pharmaceuticals, Inc. Ranks

Frequently Asked Questions

What is Amphastar Pharmaceuticals, Inc.'s annual revenue?

Amphastar Pharmaceuticals, Inc. (AMPH) reported $719.9M in total revenue for fiscal year 2025. This represents a -1.7% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Amphastar Pharmaceuticals, Inc.'s revenue growing?

Amphastar Pharmaceuticals, Inc. (AMPH) revenue declined by 1.7% year-over-year, from $732.0M to $719.9M in fiscal year 2025.

Is Amphastar Pharmaceuticals, Inc. profitable?

Yes, Amphastar Pharmaceuticals, Inc. (AMPH) reported a net income of $78.5M over the trailing 12 months to June 30, 2026. In fiscal year 2025 it reported a net income of $98.1M, with a net profit margin of 13.6%.

What is Amphastar Pharmaceuticals, Inc.'s EBITDA?

Amphastar Pharmaceuticals, Inc. (AMPH) had EBITDA of $197.3M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

How much debt does Amphastar Pharmaceuticals, Inc. have?

As of fiscal year 2025, Amphastar Pharmaceuticals, Inc. (AMPH) had $170.2M in cash and equivalents against $619.7M in long-term debt.

What is Amphastar Pharmaceuticals, Inc.'s gross margin?

Amphastar Pharmaceuticals, Inc. (AMPH) had a gross margin of 49.5% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

What is Amphastar Pharmaceuticals, Inc.'s operating margin?

Amphastar Pharmaceuticals, Inc. (AMPH) had an operating margin of 19.5% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is Amphastar Pharmaceuticals, Inc.'s net profit margin?

Amphastar Pharmaceuticals, Inc. (AMPH) had a net profit margin of 13.6% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

What is Amphastar Pharmaceuticals, Inc.'s return on equity (ROE)?

Amphastar Pharmaceuticals, Inc. (AMPH) has a return on equity of 12.4% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Amphastar Pharmaceuticals, Inc.'s free cash flow?

Amphastar Pharmaceuticals, Inc. (AMPH) generated $121.2M in free cash flow during fiscal year 2025. This represents a -29.7% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Amphastar Pharmaceuticals, Inc.'s operating cash flow?

Amphastar Pharmaceuticals, Inc. (AMPH) generated $156.1M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Amphastar Pharmaceuticals, Inc.'s total assets?

Amphastar Pharmaceuticals, Inc. (AMPH) had $1.6B in total assets as of fiscal year 2025, including both current and long-term assets.

What are Amphastar Pharmaceuticals, Inc.'s capital expenditures?

Amphastar Pharmaceuticals, Inc. (AMPH) invested $34.9M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does Amphastar Pharmaceuticals, Inc. spend on research and development?

Amphastar Pharmaceuticals, Inc. (AMPH) invested $85.8M in research and development during fiscal year 2025.

Does Amphastar Pharmaceuticals, Inc. buy back shares?

Yes, Amphastar Pharmaceuticals, Inc. (AMPH) spent $75.6M on share buybacks during fiscal year 2025, returning capital to shareholders by reducing shares outstanding.

How many shares does Amphastar Pharmaceuticals, Inc. have outstanding?

Amphastar Pharmaceuticals, Inc. (AMPH) had 45M shares outstanding as of fiscal year 2025.

What is Amphastar Pharmaceuticals, Inc.'s current ratio?

Amphastar Pharmaceuticals, Inc. (AMPH) had a current ratio of 4.02 as of fiscal year 2025, which is generally considered healthy.

What is Amphastar Pharmaceuticals, Inc.'s debt-to-equity ratio?

Amphastar Pharmaceuticals, Inc. (AMPH) had a debt-to-equity ratio of 0.79 as of fiscal year 2025. We compute it as long-term debt divided by total shareholder equity, where long-term debt is the noncurrent part of the company's borrowings, so debt due within the next twelve months is not counted.

What is Amphastar Pharmaceuticals, Inc.'s liabilities-to-equity ratio?

Amphastar Pharmaceuticals, Inc. (AMPH) had a liabilities-to-equity ratio of 1.07 as of fiscal year 2025, which is total liabilities divided by total shareholder equity. Total liabilities counts every obligation on the balance sheet (payables, deposits, insurance reserves and deferred taxes as well as borrowings), so this ratio usually runs well above debt-to-equity.

What is Amphastar Pharmaceuticals, Inc.'s return on assets (ROA)?

Amphastar Pharmaceuticals, Inc. (AMPH) had a return on assets of 6.0% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Amphastar Pharmaceuticals, Inc.'s P/E ratio?

Amphastar Pharmaceuticals, Inc. (AMPH) trades at 14.3x earnings, its market capitalization divided by $78.5M net income, trailing 12 months to June 30, 2026. The market capitalization is $1.1B as of Oct 28, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

What is Amphastar Pharmaceuticals, Inc.'s price-to-sales ratio?

Amphastar Pharmaceuticals, Inc. (AMPH) trades at 1.5x sales, its market capitalization divided by $730.0M revenue, trailing 12 months to June 30, 2026. The market capitalization is $1.1B as of Oct 28, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

What is Amphastar Pharmaceuticals, Inc.'s Altman Z-Score?

Amphastar Pharmaceuticals, Inc. (AMPH) has an Altman Z-Score of 2.45, placing it in the Grey Zone (moderate risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is Amphastar Pharmaceuticals, Inc.'s Piotroski F-Score?

Amphastar Pharmaceuticals, Inc. (AMPH) has a Piotroski F-Score of 6 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Amphastar Pharmaceuticals, Inc.'s earnings high quality?

Amphastar Pharmaceuticals, Inc. (AMPH) has an earnings quality ratio of 1.59x, considered cash-backed (high quality). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Amphastar Pharmaceuticals, Inc. cover its interest payments?

Amphastar Pharmaceuticals, Inc. (AMPH) has an interest coverage ratio of 5.51x, meaning it can comfortably cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

How financially healthy is Amphastar Pharmaceuticals, Inc.?

Amphastar Pharmaceuticals, Inc. (AMPH) scores 69 out of 100 on our Financial Health Score, indicating strong standing within its operating companies peer group. The score is the average of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.